Vericel Q3 revenue up 27% to $57.9M; raises full-year margin guidance

Vericel Corp

2024-Q3 EPS reported -$0.19 revenue$161,848,000

Total net revenue $57.9M (+27% YoY); MACI $44.7M (+19%), Burn Care $13.2M (+66%).
Gross margin 72% (+480bps YoY); net loss narrowed to $0.9M ($0.02/share) from $3.7M.
Adjusted EBITDA $10.0M (+84%, margin 17%); raised FY24 guidance: gross margin 72%, adj. EBITDA margin 22%.
FDA approved MACI Arthro for knee cartilage repair; NexoBrid pediatric indication also approved.
Cash $151M, no debt; operating cash flow $10.2M in Q3.

This headline and bullets were generated automatically by deepseek-v4-flash:cloud@v2 from the public filing. Read the source on SEC.gov before relying on any specific claim. Not investment advice. See methodology for how this pipeline works.